Over 10 States Now Require Mandatory Reporting of Syndrome Marker Tests

More than a dozen states now require laboratories and physicians to report every positive alpha-gal IgE test to state health authorities, a quiet but accelerating shift in how the United States tracks a tick-borne allergy that the CDC estimates may have affected as many as 450,000 Americans since 2010. New York is not among them, and that gap is increasingly difficult to defend.

Arkansas pioneered the requirement in September 2023, becoming the first state to treat alpha-gal syndrome as a mandatory reportable condition. The list has grown steadily since: Delaware, Iowa, Kentucky, Nebraska, North Dakota, Oregon, Rhode Island, South Carolina, Tennessee, Virginia, and West Virginia all followed. New York City operates its own reporting requirement through the city health department, but New York State as a whole does not, leaving providers outside the five boroughs with no legal obligation to flag a diagnosis that researchers at Oxford Academic's Open Forum for Infectious Diseases have described as reaching "an alarmingly high number of cases" in Suffolk County alone.

The practical consequences run downstream through every layer of the public health system. Without mandatory reporting, state officials cannot calculate how fast the condition is spreading, which counties carry the highest burden, or where to concentrate lone star tick surveillance and control resources. Clinicians treating patients with unexplained allergic reactions to red meat or dairy receive no state-level guidance calibrated to local prevalence. And patients, who often wait years before receiving an accurate diagnosis, have no system to learn from because no system is recording them.

The contrast with states that do require reporting is instructive. West Virginia made alpha-gal syndrome a reportable condition in June 2025 and within months had confirmed 14 cases, with additional investigations underway, according to the West Virginia Department of Health. The figure is almost certainly a fraction of true incidence, but it represents a baseline that New York, despite far greater tick exposure, cannot produce.

Virginia offers a parallel. Legislation passed in April 2024 took effect in September 2025, and Fairfax County's health department immediately began directing physicians and laboratory directors to report both suspected and confirmed cases. The move created the first statewide surveillance infrastructure for a condition that the CDC's 2023 MMWR report identified as concentrated in precisely the corridor stretching from Virginia northward through Maryland, Delaware, and into Suffolk County, New York.

The CDC has been explicit that its national case estimate, ranging from 96,000 to 450,000 persons affected since 2010, is almost certainly an undercount, in part because alpha-gal syndrome is not nationally notifiable and because reporting is inconsistent in high-exposure northeastern states including New York, New Jersey, and Pennsylvania. A 47-year-old New Jersey man with no prior health conditions died in the summer of 2024 in what researchers believe may be the first fatal domestic case attributable to the syndrome, a death that went unexplained for months.

Missouri introduced legislation in February 2026 to add the condition to its mandatory list. New York has introduced no comparable measure, even as the lone star tick's established range in Suffolk County has been documented by CDC data and as Stony Brook Medicine operates what it describes as the only dedicated tick-borne disease clinic in the Northeast. The surveillance infrastructure to match that clinical reality does not yet exist at the state level.